RU2015143908A - Терапевтические соединения и композиции - Google Patents
Терапевтические соединения и композиции Download PDFInfo
- Publication number
- RU2015143908A RU2015143908A RU2015143908A RU2015143908A RU2015143908A RU 2015143908 A RU2015143908 A RU 2015143908A RU 2015143908 A RU2015143908 A RU 2015143908A RU 2015143908 A RU2015143908 A RU 2015143908A RU 2015143908 A RU2015143908 A RU 2015143908A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- compound
- alkyl
- optionally substituted
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 47
- 239000000203 mixture Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 125000003118 aryl group Chemical group 0.000 claims 16
- 125000001072 heteroaryl group Chemical group 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- -1 aralkenyl Chemical group 0.000 claims 6
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 5
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000005356 cycloalkylalkenyl group Chemical group 0.000 claims 4
- 208000007475 hemolytic anemia Diseases 0.000 claims 4
- 125000004449 heterocyclylalkenyl group Chemical group 0.000 claims 4
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 208000002903 Thalassemia Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 208000005980 beta thalassemia Diseases 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 208000035623 congenital anemia Diseases 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 1
- XOHUEYCVLUUEJJ-UHFFFAOYSA-I 2,3-Diphosphoglycerate Chemical compound [O-]P(=O)([O-])OC(C(=O)[O-])COP([O-])([O-])=O XOHUEYCVLUUEJJ-UHFFFAOYSA-I 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims 1
- BQEUECRVCKCNDI-UHFFFAOYSA-N 4-[4-(2-fluoro-5-methylphenyl)-4-hydroxypiperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound CC1=CC=C(F)C(C2(O)CCN(CC2)C(=O)C=2C=CC(=CC=2)S(=O)(=O)NC=2SC=CN=2)=C1 BQEUECRVCKCNDI-UHFFFAOYSA-N 0.000 claims 1
- FKIRFDIHZTZLHM-UHFFFAOYSA-N 4-[4-(3-fluorophenyl)-4-hydroxypiperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound C1CC(O)(C=2C=C(F)C=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=NC=CS1 FKIRFDIHZTZLHM-UHFFFAOYSA-N 0.000 claims 1
- VKTRIIOQTOLRAS-UHFFFAOYSA-N 4-[4-(4-chlorophenyl)-4-hydroxypiperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=NC=CS1 VKTRIIOQTOLRAS-UHFFFAOYSA-N 0.000 claims 1
- BFBYUBBUQICKBI-UHFFFAOYSA-N 4-[4-hydroxy-4-(4-methylphenyl)piperidine-1-carbonyl]-n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound C1=CC(C)=CC=C1C1(O)CCN(C(=O)C=2C=CC(=CC=2)S(=O)(=O)NC=2SC=CN=2)CC1 BFBYUBBUQICKBI-UHFFFAOYSA-N 0.000 claims 1
- 208000030760 Anaemia of chronic disease Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 206010014490 Elliptocytosis hereditary Diseases 0.000 claims 1
- 208000001825 Hereditary elliptocytosis Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- 108700014121 Pyruvate Kinase Deficiency of Red Cells Proteins 0.000 claims 1
- 208000004622 abetalipoproteinemia Diseases 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 201000003922 congenital nonspherocytic hemolytic anemia Diseases 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 1
- 208000009601 hereditary spherocytosis Diseases 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- BAJLNYHQTYVIOS-UHFFFAOYSA-N methyl 1-[4-[(2-methylphenyl)sulfamoyl]benzoyl]-4-phenylpiperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)(C=2C=CC=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=CC=CC=C1C BAJLNYHQTYVIOS-UHFFFAOYSA-N 0.000 claims 1
- WXRMODUITVDKEN-UHFFFAOYSA-N methyl 4-phenyl-1-[4-(phenylsulfamoyl)benzoyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)(C=2C=CC=CC=2)CCN1C(=O)C(C=C1)=CC=C1S(=O)(=O)NC1=CC=CC=C1 WXRMODUITVDKEN-UHFFFAOYSA-N 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2013/072688 | 2013-03-15 | ||
| PCT/CN2013/072688 WO2014139144A1 (en) | 2013-03-15 | 2013-03-15 | Therapeutic compounds and compositions |
| PCT/CN2014/000260 WO2014139325A1 (en) | 2013-03-15 | 2014-03-13 | Therapeutic compounds and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015143908A true RU2015143908A (ru) | 2017-04-21 |
Family
ID=51535825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015143908A RU2015143908A (ru) | 2013-03-15 | 2014-03-13 | Терапевтические соединения и композиции |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US20160046579A1 (enExample) |
| EP (1) | EP2970189B1 (enExample) |
| JP (2) | JP6374413B2 (enExample) |
| CN (1) | CN105121425A (enExample) |
| AR (1) | AR095557A1 (enExample) |
| AU (1) | AU2014231564B2 (enExample) |
| BR (1) | BR112015023760A2 (enExample) |
| CA (1) | CA2903067A1 (enExample) |
| CL (1) | CL2015002767A1 (enExample) |
| CR (1) | CR20150571A (enExample) |
| ES (1) | ES2803548T3 (enExample) |
| HK (1) | HK1216175A1 (enExample) |
| IL (1) | IL241352A0 (enExample) |
| MX (1) | MX2015012882A (enExample) |
| NI (1) | NI201500140A (enExample) |
| PE (1) | PE20151793A1 (enExample) |
| PH (1) | PH12015502161A1 (enExample) |
| RU (1) | RU2015143908A (enExample) |
| SG (1) | SG11201507332SA (enExample) |
| TW (1) | TW201444797A (enExample) |
| WO (2) | WO2014139144A1 (enExample) |
| ZA (1) | ZA201506487B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014139144A1 (en) * | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| SG10201902326XA (en) | 2014-09-17 | 2019-04-29 | Celgene Car Llc | Mk2 inhibitors and uses thereof |
| CN104817490B (zh) * | 2015-05-13 | 2017-10-13 | 北京大学 | 氨基二硫代甲酸酯类化合物及其制备方法与应用 |
| ES2950348T3 (es) | 2015-12-09 | 2023-10-09 | Novartis Ag | Moduladores de receptores NMDA de tienopirimidinona y usos de los mismos |
| LT3386591T (lt) | 2015-12-09 | 2020-10-12 | Cadent Therapeutics, Inc. | Heteroaromatiniai nmda receptoriaus moduliatoriai ir jų panaudojimas |
| GB201617758D0 (en) * | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| ES2975336T3 (es) | 2016-12-22 | 2024-07-04 | Novartis Ag | Moduladores del receptor NMDA y usos de los mismos |
| DK3448859T3 (da) * | 2017-03-20 | 2019-09-23 | Forma Therapeutics Inc | Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer |
| CN107298685A (zh) * | 2017-06-29 | 2017-10-27 | 上海合全药业股份有限公司 | 一种8‑(叔丁氧羰基)‑1‑氧杂‑8‑氮杂螺[4.5]癸烷‑2‑羧酸的合成方法 |
| TWI796353B (zh) | 2017-08-15 | 2023-03-21 | 美商阿吉歐斯製藥公司 | 丙酮酸激酶調節劑及其用途 |
| LT3786160T (lt) | 2017-10-27 | 2022-09-26 | Boehringer Ingelheim International Gmbh | Piridino dariniai ir jų terapinis panaudojimas kaip trpc6 inhibitorių |
| EP3604288B1 (en) | 2018-08-02 | 2024-04-10 | Development Center for Biotechnology | Regioselective one-step process for synthesizing 2-hydroxyquinoxaline |
| ES2951872T3 (es) | 2018-08-03 | 2023-10-25 | Novartis Ag | Moduladores del receptor NMDA heteroaromáticos y usos de los mismos |
| WO2020061378A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
| JP7450610B2 (ja) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | ピルビン酸キナーゼｒの活性化 |
| US11535595B2 (en) | 2018-12-18 | 2022-12-27 | D. Western Therapeutics Institute, Inc. | Isoquinoline sulfonyl chloride acid addition salts and method of manufacture thereof |
| WO2021029450A1 (ko) * | 2019-08-09 | 2021-02-18 | 한국화학연구원 | 신규한 피리미딘 설폰아마이드 유도체 및 이를 유효성분으로 포함하는 암 예방 또는 치료용 약학 조성물 |
| MX2022003254A (es) | 2019-09-19 | 2022-04-18 | Forma Therapeutics Inc | Composiciones activadoras de piruvato cinasa r (pkr). |
| BR112022026698A2 (pt) | 2020-08-13 | 2023-02-23 | Boehringer Ingelheim Int | Tratamento da deficiência cognitiva associada à esquizofrenia |
| CN117567449A (zh) | 2020-10-13 | 2024-02-20 | 勃林格殷格翰国际有限公司 | 再加工方法 |
| CN112773800B (zh) * | 2021-01-25 | 2021-10-15 | 南通大学 | 哌啶-1-二硫代甲酸-3-甲基-1，4-二氧-1，4-二氢萘-2-甲基酯的用途 |
| WO2022170200A1 (en) | 2021-02-08 | 2022-08-11 | Global Blood Therapeutics, Inc. | 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| EP4337327A1 (en) * | 2021-05-12 | 2024-03-20 | Boehringer Ingelheim International GmbH | Pyridine derivatives with c-linked cyclic substituents as cgas inhibitors |
| CA3215920A1 (en) | 2021-05-12 | 2022-11-17 | Boehringer Ingelheim International Gmbh | Pyridine derivatives with n-linked cyclic substituents as cgas inhibitors |
| JP2025500499A (ja) | 2021-12-21 | 2025-01-09 | サイノハブ ファーマシューティカル カンパニー リミテッド | ビス（アザニリリデン）スルホニル構造を含む化合物および医薬におけるその使用 |
| CN115073422A (zh) * | 2022-07-28 | 2022-09-20 | 成都普瑞熙药业有限公司 | 一种制备4-(1-甲基-1h-吡唑-5-基)哌啶及其盐的方法 |
| ES2975743A1 (es) * | 2022-11-22 | 2024-07-12 | Moehs Iberica Sl | Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos |
| WO2024245143A1 (zh) | 2023-05-26 | 2024-12-05 | 赛诺哈勃药业（成都）有限公司 | 含二氮杂亚基磺酰结构化合物的药物组合物在治疗贫血相关疾病中的用途 |
| WO2025191185A1 (en) * | 2024-03-15 | 2025-09-18 | Domain Therapeutics | Azine-based compounds as par-2 inhibitors and therapeutic uses thereof |
| WO2025233901A1 (en) | 2024-05-09 | 2025-11-13 | Biohaven Therapeutics Ltd. | Activators of pyruvate kinase isoform m2 and methods for treating neurodegenerative disease |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL76414C (enExample) | 1949-07-23 | |||
| GB935538A (en) | 1959-04-06 | 1963-08-28 | Stop Motion Devices Corp | Stop-motion head for use on knitting machines |
| US4474599A (en) | 1982-07-14 | 1984-10-02 | The Dow Chemical Company | 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents |
| GB8325370D0 (en) | 1983-09-22 | 1983-10-26 | Fujisawa Pharmaceutical Co | Benzoxazoline and benzothiazoline derivatives |
| JPS61129129A (ja) | 1984-11-28 | 1986-06-17 | Kureha Chem Ind Co Ltd | 抗腫瘍剤 |
| FI855180A7 (fi) | 1985-01-18 | 1986-07-19 | Nissan Chemical Ind Ltd | Pyratsolisulfonamidijohdannainen, menetelmä sen valmistamiseksi ja sitä sisältävä rikkaruohomyrkky. |
| EP0246749A3 (en) | 1986-05-17 | 1988-08-31 | AgrEvo UK Limited | Triazole herbicides |
| JPS6339875A (ja) | 1986-08-05 | 1988-02-20 | Nissin Food Prod Co Ltd | ピリミジン誘導体 |
| US4775762A (en) | 1987-05-11 | 1988-10-04 | The Dow Chemical Company | Novel (1H-1,2,3-triazol-1-yl)pyridines |
| DE3813885A1 (de) | 1988-04-20 | 1989-11-02 | Schering Ag | 1-chlorpyrimidinyl-1h-1,2,4-triazol-3-sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung |
| DE3813886A1 (de) | 1988-04-20 | 1989-11-02 | Schering Ag | 1-triazinyl-1h-1,2,4-triazol-3- sulfonsaeureamide, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider, fungizider und pflanzenwachstumsregulierender wirkung |
| US5220028A (en) | 1988-10-27 | 1993-06-15 | Nissan Chemical Industries, Ltd. | Halogeno-4-methylpyrazoles |
| MY106533A (en) | 1990-02-20 | 1995-06-30 | Sumitomo Chemical Co | A 4-tert.-butyl imidazole derivative and its production and use. |
| CA2036148A1 (en) | 1990-06-29 | 1991-12-30 | Hiroki Tomioka | A 1-phenylimidazole derivative and its production and use |
| HUT65077A (en) | 1990-12-31 | 1994-04-28 | Monsanto Co | Antidoted herbicides and process for combatting the phytotoxic action of herbicidal compounds |
| AU644297B2 (en) | 1991-06-28 | 1993-12-02 | Sumitomo Chemical Company, Limited | A 1-pyridylimidazole derivative and its production and use |
| JPH0625177A (ja) | 1992-07-09 | 1994-02-01 | Nissan Chem Ind Ltd | ピラゾール誘導体及び除草剤 |
| JP3719612B2 (ja) | 1993-06-14 | 2005-11-24 | 塩野義製薬株式会社 | ヘテロ環を含有する尿素誘導体 |
| DE19541146A1 (de) | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
| FR2744449B1 (fr) | 1996-02-02 | 1998-04-24 | Pf Medicament | Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments |
| US6172005B1 (en) | 1997-03-11 | 2001-01-09 | E. I. Du Pont De Nemours And Company | Heteroaryl azole herbicides |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| DE19743435A1 (de) | 1997-10-01 | 1999-04-08 | Merck Patent Gmbh | Benzamidinderivate |
| US6214879B1 (en) | 1998-03-24 | 2001-04-10 | Virginia Commonwealth University | Allosteric inhibitors of pyruvate kinase |
| WO2000012077A1 (en) | 1998-09-01 | 2000-03-09 | Bristol-Myers Squibb Company | Potassium channel inhibitors and method |
| SK3852001A3 (en) | 1998-09-18 | 2003-03-04 | Basf Ag | 4-Aminopyrrolopyrimidines as kinase inhibitors |
| US6492408B1 (en) | 1999-07-21 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Small molecules useful in the treatment of inflammatory disease |
| DE60009319T2 (de) | 1999-09-04 | 2005-03-31 | Astrazeneca Ab | Substituierte n-phenyl-2-hydroxy-2-methyl-3,3,3-trifluorpropanamid-derivative zur erhöhung der pyruvatdehydrogenaseaktivität |
| JP2002193710A (ja) | 2000-12-25 | 2002-07-10 | Kumiai Chem Ind Co Ltd | ピリミジン又はトリアジン誘導体及び農園芸用殺菌剤 |
| WO2002089793A1 (en) | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
| US7288554B2 (en) | 2001-08-15 | 2007-10-30 | E.I. Du Pont De Nemours And Company | Ortho-substituted aryl amides for controlling invertebrate pests |
| JP2003081937A (ja) | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
| WO2003037252A2 (en) | 2001-10-30 | 2003-05-08 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003062235A1 (en) | 2002-01-17 | 2003-07-31 | Eli Lilly And Company | Modulators of acetylcholine receptors |
| EA006707B1 (ru) | 2002-03-13 | 2006-02-24 | Янссен Фармацевтика Н. В. | Сульфонилпроизводные в качестве новых ингибиторов гистон-деацетилазы |
| JP4901102B2 (ja) | 2002-05-03 | 2012-03-21 | エクセリクシス， インク． | プロテインキナーゼモジュレーターおよびその使用方法 |
| GB0215775D0 (en) | 2002-07-06 | 2002-08-14 | Astex Technology Ltd | Pharmaceutical compounds |
| DE60334386D1 (de) | 2002-08-09 | 2010-11-11 | Merck Sharp & Dohme | Tyrosinkinaseinhibitoren |
| AU2003274373A1 (en) | 2002-10-24 | 2004-05-13 | Sterix Limited | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2 |
| CN1744899A (zh) * | 2002-12-13 | 2006-03-08 | 史密丝克莱恩比彻姆公司 | 作为ccr5拮抗剂的哌啶衍生物 |
| EP1615698B1 (en) * | 2003-04-11 | 2010-09-29 | High Point Pharmaceuticals, LLC | New amide derivatives and pharmaceutical use thereof |
| BRPI0411275A (pt) | 2003-06-10 | 2006-08-01 | Kalypsys Inc | compostos de carbonila como inibidores de histona deacetilase para tratamento de doenças; composição farmacêutica; método de modular a atividade catalìtica de hdac; método de tratar doença em um indivìduo; utilização de um composto ou composição; método de inibir hdac |
| US6818631B1 (en) | 2003-08-15 | 2004-11-16 | Nippon Soda Co. Ltd. | Fungicidal pyrimidine derivatives |
| US20080051414A1 (en) | 2003-10-14 | 2008-02-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Protein Kinase Inhibitors |
| JP2008514590A (ja) | 2004-09-24 | 2008-05-08 | アストラゼネカ・アクチエボラーグ | ベンゾイミダゾール誘導体、それを含む組成物、その製造方法及びその使用 |
| WO2006038594A1 (ja) * | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| US20070249625A1 (en) | 2004-10-20 | 2007-10-25 | Jakob Busch-Petersen | Il-8 Receptor Antagonists |
| WO2006052546A2 (en) | 2004-11-04 | 2006-05-18 | Neurogen Corporation | Pyrazolylmethyl heteroaryl derivatives |
| SE0402762D0 (sv) | 2004-11-11 | 2004-11-11 | Astrazeneca Ab | Indazole sulphonamide derivatives |
| CA2606804A1 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Antimicrobial agents |
| CN101258135A (zh) | 2005-07-05 | 2008-09-03 | 阿斯利康(瑞典)有限公司 | 新化合物、其制备方法、中间体、药物组合物和其在治疗5－ht6介导的疾病例如阿尔茨海默病、认知障碍、精神分裂症相关的认知缺损、肥胖和帕金森病中的用途 |
| US20080214495A1 (en) | 2005-07-08 | 2008-09-04 | Astrazeneca Ab | Heterocyclic Sulfonamide Derivatives as Inhibitors of Factor Xa |
| EP1910342A1 (en) | 2005-07-29 | 2008-04-16 | Kalypsys, Inc. | Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease |
| AU2006278504B2 (en) | 2005-08-04 | 2013-01-17 | Sirtris Pharmaceuticals, Inc. | Imidazopyridine derivatives as sirtuin modulating agents |
| JP2007238458A (ja) | 2006-03-06 | 2007-09-20 | D Western Therapeutics Institute Inc | 新規なイソキノリン誘導体及びこれを含有する医薬 |
| WO2007108742A1 (en) | 2006-03-17 | 2007-09-27 | Astrazeneca Ab | Novel tetralins as 5-ht6 modulators |
| AU2007231594A1 (en) | 2006-03-23 | 2007-10-04 | Amgen Inc. | 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases |
| EP2001480A4 (en) | 2006-03-31 | 2011-06-15 | Abbott Lab | Indazole CONNECTIONS |
| CA2659956C (en) | 2006-08-04 | 2016-01-05 | Lewis C. Cantley | Inhibitors of pyruvate kinase and methods of treating disease |
| WO2008024284A2 (en) | 2006-08-21 | 2008-02-28 | Merck & Co., Inc. | Sulfonylated piperazines as cannabinoid-1 receptor modulators |
| JP5121717B2 (ja) | 2006-09-01 | 2013-01-16 | 大塚アグリテクノ株式会社 | Ｎ−ピリジルピペリジン化合物、その製造方法及び有害生物防除剤 |
| CN101528752A (zh) | 2006-10-16 | 2009-09-09 | 辉瑞产品公司 | 治疗性吡唑基噻吩并吡啶 |
| HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| CA2681572C (en) * | 2007-03-23 | 2014-02-11 | Icagen, Inc. | Inhibitors of ion channels |
| AU2008275927B8 (en) | 2007-07-18 | 2014-08-14 | Janssen Pharmaceutica N.V. | Sulfonamides as TRPM8 modulators |
| EP2053045A1 (en) | 2007-10-26 | 2009-04-29 | Syngenta Participations AG | Novel imidazole derivatives |
| KR20100101580A (ko) | 2007-10-26 | 2010-09-17 | 신젠타 파티서페이션즈 아게 | 신규한 이미다졸 유도체 |
| CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| RU2011108563A (ru) * | 2008-08-05 | 2012-09-10 | Таргеджен, Инк. (US) | Способы лечения талассемии |
| CA2771226A1 (en) * | 2008-08-22 | 2010-02-25 | James Madden | New bradykinin b1 antagonists |
| GB0815781D0 (en) * | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
| CA3041868C (en) | 2008-10-09 | 2023-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bis sulfonamide piperazinyl and piperidinyl activators of human pyruvatekinase |
| EP2417123A2 (en) | 2009-04-06 | 2012-02-15 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
| WO2010124114A1 (en) | 2009-04-22 | 2010-10-28 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| DK2427441T3 (en) | 2009-05-04 | 2017-03-20 | Agios Pharmaceuticals Inc | PKM2 Activators for use in the treatment of cancer |
| WO2010130638A1 (en) * | 2009-05-14 | 2010-11-18 | Evotec Ag | Sulfonamide compounds, pharmaceutical compositions and uses thereof |
| CA2944788C (en) * | 2009-06-29 | 2023-08-22 | Agios Pharmaceuticals, Inc. | Compounds, and compositions thereof, which modulate pyruvate kinase m2, and methods of making same |
| CA2787784A1 (en) | 2010-01-29 | 2011-08-04 | Dana-Farber Cancer Institute, Inc. | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
| CA2791680A1 (en) | 2010-03-01 | 2011-09-09 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| US20130109672A1 (en) | 2010-04-29 | 2013-05-02 | The United States Of America,As Represented By The Secretary, Department Of Health And Human Service | Activators of human pyruvate kinase |
| DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
| FR2967674B1 (fr) | 2010-11-23 | 2012-12-14 | Pf Medicament | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine |
| JP5837091B2 (ja) * | 2010-12-17 | 2015-12-24 | アジオス ファーマシューティカルズ， インコーポレイテッド | ピルビン酸キナーゼｍ２（ｐｋｍ２）調節剤としての新規ｎ−（４−（アゼチジン−１−カルボニル）フェニル）−（ヘテロ−）アリールスルホンアミド誘導体 |
| CA2834692A1 (en) * | 2011-05-03 | 2012-11-08 | Agios Pharmaceuticals, Inc. | Pyruvate kinase activators for use in therapy |
| CN102805860A (zh) * | 2011-05-30 | 2012-12-05 | 复旦大学 | 丙酮酸激酶2乙酰化抑制剂及其用途 |
| WO2014139144A1 (en) * | 2013-03-15 | 2014-09-18 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
-
2013
- 2013-03-15 WO PCT/CN2013/072688 patent/WO2014139144A1/en not_active Ceased
-
2014
- 2014-03-13 HK HK16104168.0A patent/HK1216175A1/zh unknown
- 2014-03-13 CN CN201480021459.8A patent/CN105121425A/zh active Pending
- 2014-03-13 ES ES14765650T patent/ES2803548T3/es active Active
- 2014-03-13 AU AU2014231564A patent/AU2014231564B2/en not_active Ceased
- 2014-03-13 RU RU2015143908A patent/RU2015143908A/ru not_active Application Discontinuation
- 2014-03-13 US US14/776,635 patent/US20160046579A1/en not_active Abandoned
- 2014-03-13 JP JP2015561914A patent/JP6374413B2/ja not_active Expired - Fee Related
- 2014-03-13 CA CA2903067A patent/CA2903067A1/en not_active Abandoned
- 2014-03-13 BR BR112015023760A patent/BR112015023760A2/pt not_active IP Right Cessation
- 2014-03-13 SG SG11201507332SA patent/SG11201507332SA/en unknown
- 2014-03-13 WO PCT/CN2014/000260 patent/WO2014139325A1/en not_active Ceased
- 2014-03-13 PE PE2015002010A patent/PE20151793A1/es not_active Application Discontinuation
- 2014-03-13 EP EP14765650.8A patent/EP2970189B1/en active Active
- 2014-03-13 MX MX2015012882A patent/MX2015012882A/es unknown
- 2014-03-14 US US14/210,583 patent/US9108921B2/en active Active
- 2014-03-14 TW TW103109338A patent/TW201444797A/zh unknown
- 2014-03-17 AR ARP140101179A patent/AR095557A1/es unknown
-
2015
- 2015-07-31 US US14/814,862 patent/US9365545B2/en active Active
- 2015-09-03 ZA ZA2015/06487A patent/ZA201506487B/en unknown
- 2015-09-09 IL IL241352A patent/IL241352A0/en unknown
- 2015-09-15 PH PH12015502161A patent/PH12015502161A1/en unknown
- 2015-09-15 CL CL2015002767A patent/CL2015002767A1/es unknown
- 2015-09-16 NI NI201500140A patent/NI201500140A/es unknown
- 2015-10-15 CR CR20150571A patent/CR20150571A/es unknown
-
2017
- 2017-03-07 JP JP2017042775A patent/JP2017105832A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CR20150571A (es) | 2016-01-06 |
| JP2017105832A (ja) | 2017-06-15 |
| HK1216175A1 (zh) | 2016-10-21 |
| US20140288081A1 (en) | 2014-09-25 |
| US20160046579A1 (en) | 2016-02-18 |
| MX2015012882A (es) | 2015-12-03 |
| US20150336931A1 (en) | 2015-11-26 |
| SG11201507332SA (en) | 2015-10-29 |
| IL241352A0 (en) | 2015-11-30 |
| PH12015502161A1 (en) | 2016-01-25 |
| EP2970189A4 (en) | 2016-08-10 |
| JP2016512203A (ja) | 2016-04-25 |
| AR095557A1 (es) | 2015-10-28 |
| ES2803548T3 (es) | 2021-01-27 |
| AU2014231564A2 (en) | 2015-10-22 |
| AU2014231564A1 (en) | 2015-09-10 |
| CA2903067A1 (en) | 2014-09-18 |
| NI201500140A (es) | 2015-11-24 |
| ZA201506487B (en) | 2016-11-30 |
| PE20151793A1 (es) | 2015-12-10 |
| US9365545B2 (en) | 2016-06-14 |
| WO2014139144A1 (en) | 2014-09-18 |
| JP6374413B2 (ja) | 2018-08-15 |
| CN105121425A (zh) | 2015-12-02 |
| AU2014231564B2 (en) | 2018-07-12 |
| TW201444797A (zh) | 2014-12-01 |
| EP2970189A1 (en) | 2016-01-20 |
| EP2970189B1 (en) | 2020-05-06 |
| CL2015002767A1 (es) | 2016-12-30 |
| BR112015023760A2 (pt) | 2017-07-18 |
| WO2014139325A1 (en) | 2014-09-18 |
| US9108921B2 (en) | 2015-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015143908A (ru) | Терапевтические соединения и композиции | |
| JP2016512203A5 (enExample) | ||
| RU2460725C2 (ru) | Новые 2-аминооксазолины в качестве лигандов taar1 | |
| JP2011503103A5 (enExample) | ||
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| JP2014511891A5 (enExample) | ||
| JP2010503688A5 (enExample) | ||
| JP2017514830A5 (enExample) | ||
| RU2014103587A (ru) | Производные циклических аминов в качестве антагонистов рецептора ер4 | |
| JP2010265321A5 (enExample) | ||
| JP2017519781A5 (enExample) | ||
| RU2015133310A (ru) | Модуляторы натриевого канала для лечения боли | |
| JP2011137006A5 (enExample) | ||
| ME02648B (me) | Jedinjenje pirazin karboksamida | |
| JP2013510125A5 (enExample) | ||
| RU2013116924A (ru) | N1/n2-лактамные ингибиторы ацетил-коа-карбоксилаз | |
| RU2016129474A (ru) | Изоксазолиновые композиции | |
| AR058388A1 (es) | DERIVADOS DE COMPUESTOS AROMATICOS SUSTITUIDOS uTILES PARA TRASTORNOS RESPIRATORIOS , COMPOSICIONES FARMACÉUTICAS Y PROCESOS PARA SU PREPARACIoN | |
| PE20050460A1 (es) | COMPUESTOS HETEROCICLICOS COMO ANTAGONISTAS CaSR (RECEPTOR SENSIBLE AL CALCIO) | |
| RU2018143994A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| RU2015116953A (ru) | Новые соединения | |
| JP2014505017A5 (enExample) | ||
| JP2006501306A5 (enExample) | ||
| RU2010117193A (ru) | Антималярийные соединения с гибкими боковыми цепями | |
| RU2009148507A (ru) | Производное тетрагидроизохинолин-1-она или его соль |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170728 |